Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry

Samankaltaisia teoksia

• Functional Improvement After RA Patients Start a New Disease Modifying Anti-rheumatic Drug Associated with Frequent Changes in DMARDs: CORRONA Database
  Tekijä: Ranganath, Veena K., et al.
  Julkaistu: (2008)
• Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol
  Tekijä: Mueller, Ruediger B., et al.
  Julkaistu: (2019)
• Hydroxychloroquine and the risk of respiratory infections among RA patients
  Tekijä: Kremer, Joel M, et al.
  Julkaistu: (2020)
• Serious infections with antirheumatic therapy: are biologicals worse?
  Tekijä: Winthrop, K L
  Julkaistu: (2006)
• Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data
  Tekijä: Pappas, Dimitrios A., et al.
  Julkaistu: (2020)